tetano
Editor, Senior Moderator
Vaccine
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.09.106 | How to Cite or Link Using DOI
Permissions & Reprints
Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults
Shuji Hatakeyamaa, b, Corresponding Author Contact Information, E-mail The Corresponding Author, Kiyoko Iwatsuki-Horimotob, Koh Okamotoa, Yoko Nukuia, Nahoko Yatad, Akira Fujitae, Shigeki Inabaf, Hiroshi Yotsuyanagia, Yoshihiro Kawaokab, c, g, h
Purchase
a Department of Infectious Diseases, Graduate School of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
b Division of Virology, Department of Microbiology and Immunology, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
c International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
d Department of Clinical Research, Tokyo Metropolitan Children's Medical Center, Japan
e Department of Pulmonary Medicine, Tokyo Metropolitan Tama Medical Center, Musashidai, Fuchu-shi, Tokyo 183-8524, Japan
f Department of Internal Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital, Kabukicho, Shinjyuku-ku, Tokyo 160-8488, Japan
g Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
h ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan
Received 9 April 2011; revised 16 August 2011; Accepted 24 September 2011. Available online 4 October 2011.
Abstract
We evaluated the immune response to a 2009 influenza A (H1N1) unadjuvanted vaccine in HIV-infected patients and assessed the boosting effect of a second dose. HIV-infected adults were enrolled and scheduled to receive the H1N1 unadjuvanted vaccine containing 15 μg of A/California/7/2009 haemagglutinin. Anti-H1N1 antibody titers were measured at enrollment and 4?8 weeks after each vaccination by using haemagglutination inhibition (HI) and virus neutralization (NT) assays. One hundred and four patients were analyzed. Seroconversion, as measured by using HI and NT assays, was observed in 52 (50.0%) patients and 49 (47.1%) patients, respectively, after the first dose. Seroconversion rate evaluated by using NT, but not HI, antibody titers were associated with HIV RNA levels of <400 copies/ml (odds ratio, 3.21; 95% CI, 1.15?8.96). Other parameters, including CD4 cell count, were not associated with seroconversion. In a cohort that received two vaccine doses at a 4?8-week interval (n = 54), the seroconversion rate and geometric mean titer for HI antibodies were 44.4% (95% CI, 30.8?58.1%) and 30.5 (95% CI, 19.9?46.9) after the first dose, respectively, and 48.1% (95% CI, 34.4?61.9%) and 39.0 (95% CI, 26.1?58.2) after the second dose, respectively. Among HIV-infected patients, the seroconversion rate was around 50% after the first dose of unadjuvanted vaccine. A second dose of vaccine had a limited boosting effect on immunity in this patient cohort.
Highlights
► We evaluate immune responses to unadjuvanted H1N1 vaccine in HIV-infected patients. ► A single dose of unadjuvanted vaccine showed poor immunogenicity. ► Even a boosting dose of unadjuvanted vaccine failed to elicit a good immune response.
http://www.sciencedirect.com/science/article/pii/S0264410X11015489
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.09.106 | How to Cite or Link Using DOI
Permissions & Reprints
Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults
Shuji Hatakeyamaa, b, Corresponding Author Contact Information, E-mail The Corresponding Author, Kiyoko Iwatsuki-Horimotob, Koh Okamotoa, Yoko Nukuia, Nahoko Yatad, Akira Fujitae, Shigeki Inabaf, Hiroshi Yotsuyanagia, Yoshihiro Kawaokab, c, g, h
Purchase
a Department of Infectious Diseases, Graduate School of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
b Division of Virology, Department of Microbiology and Immunology, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
c International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
d Department of Clinical Research, Tokyo Metropolitan Children's Medical Center, Japan
e Department of Pulmonary Medicine, Tokyo Metropolitan Tama Medical Center, Musashidai, Fuchu-shi, Tokyo 183-8524, Japan
f Department of Internal Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital, Kabukicho, Shinjyuku-ku, Tokyo 160-8488, Japan
g Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
h ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan
Received 9 April 2011; revised 16 August 2011; Accepted 24 September 2011. Available online 4 October 2011.
Abstract
We evaluated the immune response to a 2009 influenza A (H1N1) unadjuvanted vaccine in HIV-infected patients and assessed the boosting effect of a second dose. HIV-infected adults were enrolled and scheduled to receive the H1N1 unadjuvanted vaccine containing 15 μg of A/California/7/2009 haemagglutinin. Anti-H1N1 antibody titers were measured at enrollment and 4?8 weeks after each vaccination by using haemagglutination inhibition (HI) and virus neutralization (NT) assays. One hundred and four patients were analyzed. Seroconversion, as measured by using HI and NT assays, was observed in 52 (50.0%) patients and 49 (47.1%) patients, respectively, after the first dose. Seroconversion rate evaluated by using NT, but not HI, antibody titers were associated with HIV RNA levels of <400 copies/ml (odds ratio, 3.21; 95% CI, 1.15?8.96). Other parameters, including CD4 cell count, were not associated with seroconversion. In a cohort that received two vaccine doses at a 4?8-week interval (n = 54), the seroconversion rate and geometric mean titer for HI antibodies were 44.4% (95% CI, 30.8?58.1%) and 30.5 (95% CI, 19.9?46.9) after the first dose, respectively, and 48.1% (95% CI, 34.4?61.9%) and 39.0 (95% CI, 26.1?58.2) after the second dose, respectively. Among HIV-infected patients, the seroconversion rate was around 50% after the first dose of unadjuvanted vaccine. A second dose of vaccine had a limited boosting effect on immunity in this patient cohort.
Highlights
► We evaluate immune responses to unadjuvanted H1N1 vaccine in HIV-infected patients. ► A single dose of unadjuvanted vaccine showed poor immunogenicity. ► Even a boosting dose of unadjuvanted vaccine failed to elicit a good immune response.
http://www.sciencedirect.com/science/article/pii/S0264410X11015489